Dr. Seshan’s research interests are in the area of methods for the analysis of high throughput data, specifically from genomic profiling such as DNA sequencing and copy number and methylation arrays. He developed with Dr. Adam Olshen (University of California, San Francisco) the CBS algorithm for the analysis of DNA copy number data and has extended the method to allele copy number estimation. He is collaborating with Drs. Colin Begg, Adam Olshen and Irina Ostrovnaya on extending these methods to distinguish second cancers from metastases. He published, in collaboration with Dr. Ronglai Shen, the FACETS algorithm to estimate the allele specific copy numbers and tumor cell fraction using sequencing data. This algorithm is being adopted for use in the DNA sequencing analysis pipeline within and outside MSK. He is responsible for the research computing environment for the members of the department.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Venkatraman Seshan discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures